Sofiva Genomics Co.,Ltd. (TPEX:6615)
Taiwan · Delayed Price · Currency is TWD 34.05
-0.30 (-0.87%)
At close: Feb 11, 2026
Sofiva Genomics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -10.18 | 18.43 | 11.53 | 42.78 | 56.98 | 34.62 |
Depreciation & Amortization | 42.34 | 41.62 | 41.34 | 42.79 | 41.95 | 48.17 |
Loss (Gain) From Sale of Assets | 0 | - | - | -0.02 | - | -0 |
Loss (Gain) on Equity Investments | -25.05 | -25.35 | -23.67 | -41.9 | -31.05 | -17.5 |
Stock-Based Compensation | 0.01 | -0.73 | 1.07 | 2.68 | 2.87 | 1.87 |
Provision & Write-off of Bad Debts | -0.01 | - | 0 | -0.49 | -0.14 | -0.35 |
Other Operating Activities | 4.19 | 8.46 | -3.92 | -2.99 | 1.58 | -13.54 |
Change in Accounts Receivable | 6.75 | 5.6 | -2.23 | 0.94 | -12.39 | 2.33 |
Change in Inventory | 6.2 | -4.61 | 15.29 | -15.52 | 8.55 | -15.84 |
Change in Accounts Payable | -6.34 | -9.25 | -18.89 | -3.64 | 7.72 | 11.39 |
Change in Unearned Revenue | -1.38 | 1 | -1.34 | -0.58 | -0.56 | 0.69 |
Change in Other Net Operating Assets | -5.12 | -0.5 | 4.5 | -6.92 | 4.56 | 8.98 |
Operating Cash Flow | 11.42 | 34.69 | 23.7 | 17.14 | 80.07 | 60.82 |
Operating Cash Flow Growth | -52.57% | 46.38% | 38.30% | -78.60% | 31.65% | -39.69% |
Capital Expenditures | -0.47 | -16.92 | -21.01 | -33.53 | -8.16 | -15.47 |
Sale of Property, Plant & Equipment | 0.04 | - | - | 0.1 | - | 0 |
Sale (Purchase) of Intangibles | -6.95 | -7.2 | -3.55 | -2.17 | -4.49 | -0.45 |
Investment in Securities | - | 9.13 | 7.93 | -20.95 | - | -30.2 |
Other Investing Activities | -6.77 | 4.33 | 6.65 | 3.07 | 2.62 | -0.27 |
Investing Cash Flow | -14.15 | -10.66 | -9.99 | -53.48 | -10.03 | -46.38 |
Long-Term Debt Repaid | - | -15.81 | -14.74 | -15.75 | -15.54 | -15.42 |
Total Debt Repaid | -15.87 | -15.81 | -14.74 | -15.75 | -15.54 | -15.42 |
Net Debt Issued (Repaid) | -15.87 | -15.81 | -14.74 | -15.75 | -15.54 | -15.42 |
Issuance of Common Stock | - | 12.07 | - | - | 1.12 | 0.55 |
Common Dividends Paid | -6.48 | -4.27 | -21.36 | -42.73 | -29.77 | -55.17 |
Other Financing Activities | -0.55 | -0.55 | -0.57 | -0.18 | -0 | - |
Financing Cash Flow | -22.9 | -8.57 | -36.67 | -58.65 | -44.19 | -70.05 |
Foreign Exchange Rate Adjustments | 0.08 | -0.19 | -0.05 | -0.18 | 0.29 | -0.5 |
Net Cash Flow | -25.55 | 15.27 | -23.01 | -95.18 | 26.14 | -56.11 |
Free Cash Flow | 10.95 | 17.77 | 2.69 | -16.4 | 71.91 | 45.35 |
Free Cash Flow Growth | 52.24% | 560.18% | - | - | 58.55% | -45.23% |
Free Cash Flow Margin | 2.78% | 3.92% | 0.58% | -3.31% | 14.14% | 9.28% |
Free Cash Flow Per Share | 0.51 | 0.82 | 0.13 | -0.77 | 3.38 | 2.12 |
Cash Interest Paid | 0.89 | 1.07 | 1.24 | 1.44 | 1.69 | 1.92 |
Cash Income Tax Paid | - | -3.23 | 1.34 | 7.61 | 5.19 | 16.25 |
Levered Free Cash Flow | 16.19 | 10.12 | 2.66 | -20.41 | 63.61 | 34.08 |
Unlevered Free Cash Flow | 16.77 | 10.81 | 3.47 | -19.48 | 64.7 | 35.31 |
Change in Working Capital | 0.12 | -7.75 | -2.66 | -25.72 | 7.88 | 7.55 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.